The study intervention focuses on exploring the use of angiotensin II as a primary vasopressor compared to norepinephrine in cardiac surgery patients to investigate whether angiotensin II can reduce the occurrence of moderate/severe acute kidney injury (AKI). Despite its potential, as suggested by trials involving surgical patients, there is currently no human data confirming its effectiveness in preventing moderate/severe AKI in this context. The intervention aims to address this gap by evaluating angiotensin II's impact compared to norepinephrine.

Start Date01 Jan 2025

Sponsor / Collaborator

Westfälische Wilhelms-Universität Münster

[+1]

NCT06487585 / Not yet recruitingPhase 4

Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery (ANG-First Trial)

The purpose of this research is to evaluate the use of Angiotensin II in patients with low blood pressure post-surgery. Your information will be collected for 28 days post the procedure and initiation of the study drug to assess for safety events and complications.

Start Date20 Aug 2024

Sponsor / Collaborator

University of Maryland St. Joseph Medical Center, LLC

NCT06351150 / Not yet recruitingPhase 3

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial to Evaluate the Efficacy and Safety of Angiotensin II Injection in the Background Treatment of Catecholamines and Other Vasopressors in Chinese Adult Patients With Refractory Distributive Shock

A randomized, double-blind, placebo-controlled study on the treatment of refractory distributed shock with angiotensin II injection, with a random ratio of 1:1. Assuming a success rate of 25% for the main therapeutic endpoint in the control group and 50% for the experimental group, a total of 214 subjects will be enrolled, including 107 in the experimental group and 107 in the control group.

Start Date01 May 2024

Sponsor / Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

100 Clinical Results associated with Angiotensin II Acetate

100 Translational Medicine associated with Angiotensin II Acetate

100 Patents (Medical) associated with Angiotensin II Acetate

10,787

Literatures (Medical) associated with Angiotensin II Acetate

31 Dec 2024·Renal Failure

Sulforaphane regulates AngII-induced podocyte oxidative stress injury through the Nrf2-Keap1/ho-1/ROS pathway

Article

Author: Lu, Wen

OBJECTIVEThis study aimed to investigate the therapeutic effects of sulforaphane and the role of the Nrf2-Keap1/HO-1/ROS pathway in AngII-induced oxidative stress in podocyte injury.METHODSMouse mpc5 podocytes were divided into four groups: control (Con), AngII, AngII + sulforaphane (AngII + SFN), and control + sulforaphane (Con + SFN). Western blotting was used to detect protein expression of Nrf2-Keap1, antioxidant enzyme HO-1, and apoptosis-related proteins. ROS levels were measured using a ROS assay kit, and cell survival and viability were assayed using the CCK-8 kit. Molecular interactions between Nrf2 and sulforaphane were analyzed computationally.RESULTSCompared with the Con group, podocytes treated with AngII alone exhibited inhibited proliferation, reduced cell viability, lower Bcl-2 expression, and higher cleaved caspase 3 expression. In the presence of sulforaphane, AngII group showed a mild inhibition on podocyte proliferation but did not induce the aforementioned changes in Bcl-2 and cleaved caspase 3 expression. Similarly, compared to the Con group, AngII treatment alone had lower Nrf2 expression and higher Keap1 expression in podocytes, accompanied by a significant decrease in ROS content. However, in the presence of sulforaphane, AngII failed to induce increases in Nrf2 and a decrease in Keap1 expression, as well as ROS levels. Furthermore, cells treated with sulforaphane exhibited higher HO-1 levels than control cells, and co-incubation with AngII did not alter HO-1 levels. Computational modeling revealed hydrophobic interactions between sulforaphane and the amino acid LYS-462 of Nrf2, as well as hydrogen bonding with amino acid HIS-465. The binding score between sulforaphane and Nrf2 was -4.7.CONCLUSIONSulforaphane alleviated AngII-induced podocyte oxidative stress injury via the Nrf2-Keap1/HO-1/ROS pathway, providing new insights into therapeutic compounds for mitigating chronic kidney disease.

31 Dec 2024·Gut Microbes

Dietary fiber intake impacts gut bacterial and viral populations in a hypertensive mouse model

Article

Author: Xie, Liang ; Nakai, Michael ; Avellaneda-Franco, Laura ; Barr, Jeremy J. ; Marques, Francine Z.

The gut microbiome is an emerging factor in preventing hypertension, yet the influence of gut bacteriophages, viruses infecting bacteria, on this condition remains unclear. Bacteriophage-bacteria interactions, which impact the gut microbiome, are influenced differentially by temperate and virulent bacteriophages. However, the standard technique for studying viral populations, viral-like particles (VLPs)-metagenomes, often overlook prophages, the intracellular stage of temperate bacteriophages, creating a knowledge gap. To address this, we investigated alterations in extracellular and intracellular bacteriophages, alongside bacterial populations, in the angiotensin II-hypertension model. We sequenced VLPs and bulk DNA from cecal-colonic samples collected from male C57BL/6J mice implanted with minipumps containing saline or angiotensin II. We assembled 106 bacterial and 816 viral genomes and found that gut viral and bacterial populations remained stable between hypertensive and normotensive mice. A higher number of temperate viruses were observed across all treatments. Although temperate viruses outnumbered virulent viruses, sequencing of both VLPs and bulk revealed that virions from virulent viruses were more abundant in the murine gut. We then evaluated the impact of low- and high-fiber intake on gut microbiome composition in the angiotensin II model. Fiber intake significantly influenced the gut microbiome composition and hypertension development. Mice receiving high-fiber had lower blood pressure, a higher bacterial-encoded carbohydrate-associated enzyme, and a higher total relative abundance of temperate viruses than those receiving low-fiber. Our findings suggest that phages are not associated with hypertension development in the angiotensin II model. However, they support a complex diet-bacteria/phage interaction that may be involved in blood pressure regulation.

31 Dec 2024·Journal of Pharmaceutical Policy and Practice

The annual economic burden incurred by heart failure patients in Vietnam: a retrospective analysis

Article

Author: Nguyen, Pol Van ; Nguyen, Huong Thi Thanh ; Vo, Trung Quang ; Tran, Hien Thi Bich ; Dao, Tien Duc ; Vu, Quynh Van

IntroductionHeart failure (HF) is a chronic condition associated with substantial mortality and hospitalisation, resulting in costly inpatient visits. The healthcare systems of several countries, including Vietnam, experience considerable difficulty in dealing with the enormous fiscal burden presented by HF. This study aims to analyse the direct medical costs associated with HF inpatient treatment from the hospital perspective.Materials and methodsThis study retrospectively analysed the electronic medical records of patients diagnosed with HF from 2018 to 2021 at Military Hospital 175 in Vietnam. The sample consisted of 906 hospitalised patients (mean age: 71.2 ± 14.1 years). The financial impact of HF was assessed by examining the direct medical expenses incurred by the healthcare system, and the costs of pharmaceutical categories used in treatment were explored.ResultsThe cumulative economic burden of HF from 2018 to 2021 was US$1,068,870, with annual costs ranging from US$201,670 to US$443,831. Health insurance covered 72.7% of these costs. Medications and infusions, and medical supplies accounted for the largest expenses, at 29.8% and 22.1%, respectively. The medication HF group accounted for 13.01% of these expenses, of which the costliest medications included nitrates (2.57%), angiotensin II receptor blockers (0.51%), ivabradine (0.39%), diuretics (0.24%), and mineralocorticoid receptor antagonists (0.23%). Comorbidities and the length of hospital stay significantly influenced annual treatment costs.ConclusionThe study reveals that HF significantly impacts Vietnam's healthcare system and citizens, requiring a comprehensive understanding of its financial implications and efficient management of medical resources for those diagnosed. This study highlights the substantial economic burden of HF on Vietnam's healthcare system, with medication costs, particularly antithrombotic drugs, representing the largest expense. Most healthcare costs were covered by health insurance, and expenses were significantly influenced by comorbidity and length of hospital stay. These findings can inform healthcare policy, resource allocation and optimise management strategies in Vietnam.

News (Medical) associated with Angiotensin II Acetate

15 Oct 2024

·www.biospace.com

Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024

WALTHAM, Mass.--(BUSINESS WIRE)-- Innoviva Specialty Therapeutics, Inc. , a biotechnology company focused on delivering innovative therapies in critical care and infectious diseases, announced today the presentation of data from three clinical abstracts and two oral presentations on the company’s pipeline and Commercial portfolio during IDWeek 2024 , October 16-19, 2024, in Los Angeles, CA. “Our clinical program continues to provide important findings from recent sub-analyses that add meaningful new insights for healthcare professionals managing difficult-to-treat and antimicrobial-resistant pathogens,” said David Altarac, MD, Chief Medical Officer at Innoviva Specialty Therapeutics. “We are pleased with the progress of our development product zoliflodacin, which recently completed the pivotal phase 3 trial conducted with our partner the Global Antibiotics Research Development Partnership. If approved, zoliflodacin could lead to the first new oral antibiotic to treat gonorrhea in decades.” IDWeek 2024 Clinical Presentations Oral Presentation Addressing a growing global threat through a novel public-private development partnership David Altarac, MD, Chief Medical Officer, Innoviva Specialty Therapeutics Friday, October 18, 2024 8:00 am – 9:00 am PT Petree C Oral Presentation Activity of Sulbactam-durlobactam and Standard-of-Care Antibiotics against Acinetobacter baumannii-calcoaceticus complex isolates acquired from Hospitalized Patients in the United States (2023 – 2024) Tomefa E. Asempa, PharmD, Hartford Hospital Saturday, October 19, 2024 10:54-11:06 am PT Room 403A Poster #P-1103 In Vitro Activity of Zoliflodacin Against Baseline Neisseria gonorrhoeae Isolates from US Participants in a Global Phase 3 Randomized Controlled Trial Sarah McLeod, PhD, Innoviva Specialty Therapeutics Friday, October 18, 2024 12:15-1:30 pm PT, Hall J&K Poster #P-1251 Pharmacometric Analyses to Support Dose Selection of Zoliflodacin, a First-in-Class Oral Antibiotic Being Developed for the Treatment of Uncomplicated Gonorrhea Sujata M. Bhavnani, MD, Institute for Clinical Pharmacodynamics Friday, October 18, 2024 12:15-1:30 pm PT, Hall J&K Time Poster# P-1532 Surveillance of Eravacycline Against CLINICAL Pathogens, including Resistant Isolates, Collected Worldwide from Multiple Infection Sites During 2018-2022 Kristie Zappas, PharmD, Innoviva Specialty Therapeutics Friday, October 18, 2024 12:15-1:30 pm PT, Halls JK About Innoviva Specialty Therapeutics Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., is focused on delivering innovative therapies in critical care and infectious disease. Innoviva Specialty Therapeutics’ products, through its affiliate, La Jolla Pharmaceutical Company, include GIAPREZA ® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA ® (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Innoviva Specialty Therapeutics’ product, through its affiliate, Entasis Therapeutics Inc., include XACDURO ® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex ( Acinetobacter ). For more information about Innoviva Specialty Therapeutics, please visit here . Contacts Media Contact : David Patti Innoviva Corporate Communications David.patti@inva.com 908.421.5971

Phase 3Drug ApprovalQualified Infectious Disease Product

04 Sep 2024

·www.businesswire.com

Innoviva to Participate in Upcoming Investor Conferences

BURLINGAME, Calif.--( BUSINESS WIRE )--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in September: H.C. Wainwright 26th Annual Global Investment Conference Format: Corporate Presentation Date: Tuesday, September 10, 2024 Time: 10:30 a.m. Eastern Time 2024 Cantor Fitzgerald Global Healthcare Conference Format: Fireside chat Date: Wednesday, September 18, 2024 Time: 3:40 p.m. Eastern Time Live webcasts of the presentations can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website at https://investor.inva.com/presentations-events . Archived replays of the webcasts will be available following the presentation dates. About Innoviva Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults. ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies.

Drug ApprovalAcquisition

02 Sep 2024

·www.pharmaceutical-technology.com

ESC 2024: Single-pill hypertension combo delivers positive results

Caption: At the ESC Congress, the George Institute for Global Health presented positive data from a clinical trial investigating a single pill-combination for mild-to-moderate hypertension. Credit: franckreporter via Getty Images. Kicking off the second day of the European Society of Cardiology (ESC) Congress, researchers presented data suggesting that a single-pill combination of anti-hypertensive drugs could be a viable option as a first-line treatment. As per results presented at the ESC Congress on 30 August, a Phase III placebo-controlled trial (NCT04518306) investigated a single-pill combination therapy for the initial treatment of hypertension. Dubbed GMRx2, the pill combines the active ingredients telmisartan, an angiotensin II antagonist, amlodipine, and indapamide. Amlodipine is a voltage-dependent L Type calcium channel blocker and indapamide is a diuretic drug. Boehringer Ingelheim markets the former drug as Micardis, whilst Viatris sells amplodipine as Norvasc, and Mylan markets the indapamide as Tensaid. London, UK-based George Medicines is developing this triple combination and filed a US Food and Drug Administration new drug application for the pill in August 2024. “Globally, most people treated for high blood pressure (BP) do not achieve adequate control, primarily due to continued use of low-efficacy regimens including monotherapy,” said Dr. Anthony Rogers, the acting director of the cardiovascular division of the George Institute for Global Health, Sydney, Australia. “Single-pill combinations of different low-dose drugs hold promise for improving hypertension management by virtue of additive benefits, rapid action and a low risk of adverse events,” he said while presenting the data. George Medicines is a spinout from George Institute for Global Health. Rogers, the principal investigator of the international study, shared trial results showing that, in a population with mild-to-moderate blood pressure elevation, both dose-versions of the single pill combination were well-tolerated and achieved clinically relevant blood pressure reductions compared with placebo. Furthermore, clinic blood pressure control was achieved in 37% of participants with placebo, compared to 65% and 70% of patients in the GMRx2 quarter- and half-dose cohorts, respectively. See Also: Novavax wins FDA emergency approval for updated Covid-19 vaccine Combating Pharmaceutical Crime with On-Dose Authentication “The availability of a single-pill combination could help to reduce current therapeutic inertia, helping patients achieve BP control quickly in a small number of steps, with potential benefits for improved adherence,” explained Rodgers.

Clinical ResultPhase 3VaccineDrug ApprovalEmergency Use Authorization

100 Deals associated with Angiotensin II Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Angiotensin II Acetate	C01CX09	DB11842

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Distributive shock	EU	PAION AG	23 Aug 2019
Distributive shock	NO	PAION AG	23 Aug 2019
Distributive shock	IS	PAION AG	23 Aug 2019
Distributive shock	LI	PAION AG	23 Aug 2019
Hypotension	IS	PAION AG	23 Aug 2019
Hypotension	NO	PAION AG	23 Aug 2019
Hypotension	LI	PAION AG	23 Aug 2019
Hypotension	EU	PAION AG	23 Aug 2019
Shock, Septic	EU	PAION AG	23 Aug 2019
Shock, Septic	IS	PAION AG	23 Aug 2019
Shock, Septic	LI	PAION AG	23 Aug 2019
Shock, Septic	NO	PAION AG	23 Aug 2019
Shock	US	La Jolla Pharma LLC	21 Dec 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Sepsis	Phase 2	AU	La Jolla Pharmaceutical Co.	01 Mar 2015
Shock	Phase 2	BE	La Jolla Pharmaceutical Co.	01 Mar 2015
Shock	Phase 2	GB	La Jolla Pharmaceutical Co.	01 Mar 2015
Shock	Phase 2	DE	La Jolla Pharmaceutical Co.	01 Mar 2015
Shock	Phase 2	FR	La Jolla Pharmaceutical Co.	01 Mar 2015
Shock	Phase 2	CH	La Jolla Pharmaceutical Co.	01 Mar 2015
Shock	Phase 2	NZ	La Jolla Pharmaceutical Co.	01 Mar 2015
Shock	Phase 2	AU	La Jolla Pharmaceutical Co.	01 Mar 2015
Shock	Phase 2	FI	La Jolla Pharmaceutical Co.	01 Mar 2015
Shock	Phase 2	CA	La Jolla Pharmaceutical Co.	01 Mar 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04558359 (CTgov)	Phase 4	Acute Kidney Injury \| Shock, Septic	30	Standard of Care (Standard of Care Cohort)	bclhqoxayy(wtljgnxlfd) = xwtryffvor ylavjtxvsx (ljhglkfxav, rkrttmwxkp - txmpoukbak) View more	-	04 Sep 2024
				Angiotensin II (Angiotensin II Cohort)	bclhqoxayy(wtljgnxlfd) = jlpcxyyjsx ylavjtxvsx (ljhglkfxav, wfumpznnir - uoocxyjkqm) View more
NCT01393782 (ATHOS, CTgov)	Phase 1	Shock, Septic \| Shock \| Hypotension	20	Angiotensin II (Angiotensin)	nuyhgavfsa(pfnwwkzzrh) = lwpcgueddu keanuufcti (dsomrclebe, orqikdbtke - nfwdebuvdz) View more	-	12 Apr 2024
				Angiotensin II (Control)	nuyhgavfsa(pfnwwkzzrh) = sqpopsebjb keanuufcti (dsomrclebe, qzghrmipgu - mnnpegnfon) View more
NCT02338843 (ATHOS-3, Pubmed \| Ann Intensive Care)	Phase 3	Respiratory Distress Syndrome, Acute	81	Angiotensin-II	prkkkbekiv(yfxtrjcmsn) = okzdlabzcd uboctpywya (dddwsqnulv ) View more	Positive	16 Dec 2023
				Placebo	prkkkbekiv(yfxtrjcmsn) = pcugfyjehr uboctpywya (dddwsqnulv ) View more
NCT02338843 (ATHOS-3, Pubmed)	Phase 3	Shock	321	Angiotensin II	aaipniowkj(uxsdkeeyjt): HR = 0.509 (95% CI, 0.274 - 0.945), P-Value = 0.03 View more	-	05 May 2023
				Placebo
NCT04529005 (CTgov)	Phase 4	Transplant complication \| Shock \| Hypotension	20	Angiotensin II	ugmeqcyuwm(mqrelsfedr) = kgasmxqwtc gflefidfzw (uacnubxapc, nmkalzeviv - rvdvmrucrz) View more	-	21 Dec 2022
ASN2022	Not Applicable	GSTM1 deficiency	-	Angiotensin II	epdimwebkg(kxxyhplgwt) = icdoaxzqns llrdkbczvw (ezuaaocide )	-	05 Nov 2022
				Angiotensin II	epdimwebkg(kxxyhplgwt) = hbiiexdtkc llrdkbczvw (ezuaaocide )
Pubmed \| Anesth Analg	Not Applicable	renin plasma concentration \| Δ-renin levels \| vasoplegia	40	Angiotensin II	emhfjyrjqc(orlizuvwqz) = fxpwynnvqi gsoufngbum (sdhfcciuil, 21.9 - 211.4)	Positive	01 May 2022
				Norepinephrine	emhfjyrjqc(orlizuvwqz) = arxkxjztps gsoufngbum (sdhfcciuil, 62.9 - 317.0)
Pubmed \| J Intensive Care Med	Not Applicable	Shock	-	Angiotensin II	(kihlarocvs) = aohjagbprv sshiybskfx (yvlqzpezfj, 6.4 - 12.1) View more	Positive	01 Jan 2022
ACTRIMS2021	Not Applicable	Multiple Sclerosis	-	Angiotensin II	cijkvizmoc(gacnktbfsi) = jjvwlybvou ojnoxghanv (nktijlnovq ) View more	Positive	01 Jul 2021
Pubmed \| Chest	Not Applicable	Shock lactate concentration \| vasopressin	270	Angiotensin II	hnbrctljgi(ihzxryhncm) = occurred in 28 patients (10%) dmbdmsguql (eyrfatsztt ) View more	Positive	01 Feb 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis